소 호흡기질환 치료 시장 : 제품 유형, 투여 경로, 치료 유형, 동물 유형, 유통 채널, 최종사용자별 - 시장 예측(2026-2032년)

The Bovine Respiratory Disease Treatment Market is projected to grow by USD 3.84 billion at a CAGR of 8.05% by 2032.

Introduction

Bovine respiratory disease (BRD) remains one of the most economically significant health challenges in cattle production, particularly in feedlot, dairy calf, and stocker operations. The condition is multifactorial, involving viral and bacterial pathogens, stress, commingling, transportation, nutrition, housing, and immune status. Veterinary authorities and academic extension programs consistently identify BRD as a leading cause of morbidity, treatment cost, production loss, and mortality in young cattle.

The bovine respiratory disease treatment landscape is shaped by the need to improve animal welfare, protect productivity, and support responsible antimicrobial use. Treatment decisions increasingly combine clinical examination, vaccination history, risk stratification, diagnostics, and post-treatment monitoring. As regulators, producers, veterinarians, and food companies intensify scrutiny of antimicrobial stewardship, the market is moving toward evidence-based BRD treatment protocols, earlier respiratory disease detection, targeted therapy, and integrated prevention strategies.

Transformative Shifts in BRD Treatment

The BRD treatment landscape is shifting from reactive, broad-based intervention toward preventive, data-informed herd health management. Vaccination programs, metaphylaxis decisions, preconditioning, biosecurity, nutrition, and low-stress handling are being aligned with therapeutic choices to reduce disease incidence and improve treatment outcomes. This shift is supported by veterinary guidance emphasizing accurate diagnosis, treatment records, responsible antimicrobial administration, and adherence to labeled withdrawal times.

Regulatory pressure is also changing product selection and clinical behavior. In the United States, medically important antimicrobials used in food-producing animals require veterinary oversight, and similar antimicrobial stewardship frameworks are advancing in Europe, Canada, and other major cattle-producing markets. At the same time, diagnostic tools, chute-side data capture, precision livestock monitoring, and herd management software are helping veterinarians distinguish high-risk animals, evaluate response to therapy, and reduce unnecessary antimicrobial exposure.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to affect bovine respiratory disease treatment by improving disease detection, risk scoring, and treatment decision support. Computer vision, acoustic monitoring, wearable sensors, feeding behavior analytics, and machine learning models can identify changes in activity, rumination, temperature, cough patterns, and feed intake that may precede visible clinical signs. These tools are most valuable when validated against veterinary diagnosis and integrated with farm-level records.

AI's cumulative impact is expected to be strongest in antimicrobial stewardship, labor efficiency, and treatment outcome analysis. By flagging animals at higher risk, AI-enabled livestock health systems can support earlier examination and more targeted therapy, while treatment outcome analytics can help veterinarians refine BRD protocols over time. However, adoption depends on data quality, model transparency, interoperability, farm connectivity, cybersecurity, and clear veterinary accountability. AI should augment, not replace, licensed veterinary judgment in BRD treatment.

Key Regional Insights

In Asia-Pacific, growth in dairy and beef demand, expanding commercial farms, and government attention to food security are increasing the need for structured bovine respiratory disease prevention and treatment programs. China, India, Japan, South Korea, and Australia represent distinct demand profiles, ranging from large cattle populations and smallholder systems to highly regulated, technology-enabled production environments. Regional adoption is shaped by farm consolidation, vaccination access, veterinary service availability, climatic stress, long-distance animal movement, and rising expectations for safe animal protein.

North America remains a leading region for BRD treatment adoption due to large feedlot capacity, established veterinary infrastructure, formal veterinary-client-patient relationships, and extensive use of herd health protocols. Latin America, led by Brazil and Mexico, is influenced by export-oriented beef production and the need to maintain animal health standards across large, geographically diverse operations. Europe is shaped by strict antimicrobial stewardship policies, strong veterinary oversight, pharmacovigilance systems, and continued investment in vaccination, diagnostics, and welfare compliance. The Middle East shows rising demand where food security policies, high-value dairy operations, heat stress management, and import-dependent supply chains are increasing the need for reliable veterinary medicines. Africa is seeing gradual demand development as dairy modernization, cattle population expansion, transboundary disease control, and veterinary access initiatives increase the need for practical respiratory disease management.

Key Group Insights

ASEAN markets are increasingly focused on livestock modernization, dairy development, and veterinary capacity building, creating opportunities for BRD treatment protocols that are practical for mixed commercial and smallholder systems. GCC countries place emphasis on food security, high-value dairy operations, controlled-environment animal production, and dependable veterinary supply chains, which supports demand for preventive respiratory health programs and reliable treatment access.

The European Union strongly influences global BRD treatment practices through antimicrobial reduction policies, pharmacovigilance, prescription controls, and animal welfare standards. BRICS countries collectively represent large cattle inventories, fast-changing protein demand, and diverse veterinary access conditions, making scalable diagnostics, vaccination coverage, and affordable treatment options important. G7 markets typically lead in regulatory oversight, research adoption, antimicrobial stewardship, and digital herd health systems. NATO members overlap significantly with advanced veterinary medicine markets where animal health security, supply resilience, biosecurity, cross-border disease surveillance, and continuity of essential veterinary products are increasingly strategic priorities.

Key Country Insights

The United States is a core BRD treatment market because of its large feedlot sector, veterinary oversight requirements, established antimicrobial use regulations, and extensive research base. Canada has similar stewardship priorities, strong beef and dairy systems, and structured veterinary governance, while Mexico combines domestic beef and dairy demand with cross-border cattle trade dynamics that heighten the importance of disease prevention and treatment documentation. Brazil's large beef industry creates substantial need for scalable respiratory disease management across diverse production systems, and Australia's extensive cattle systems place emphasis on preventive management, animal movement controls, biosecurity, welfare assurance, and export compliance.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by strong veterinary governance, antimicrobial reduction goals, dairy-beef integration, and high expectations for traceability and responsible medicine use. Russia maintains demand linked to domestic livestock development, regional supply considerations, climatic stressors, and efforts to strengthen veterinary capacity. China and India are major long-term opportunities due to herd size, dairy modernization, food security policy, and rising demand for animal protein, though farm structure, diagnostic access, and veterinary service coverage vary widely. Japan and South Korea emphasize high standards, traceability, biosecurity, and regulated veterinary care, supporting premium treatment protocols and technology-enabled monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated BRD programs that combine vaccination, nutrition, biosecurity, transportation management, diagnostics, low-stress handling, and evidence-based treatment protocols. Organizations that support veterinarians with decision tools, continuing education, pharmacovigilance data, residue prevention guidance, and clear labeling support will be better positioned as antimicrobial stewardship expectations increase.

Suppliers should also invest in rapid diagnostics, data interoperability, AI-assisted monitoring, and treatment outcome analytics that support earlier intervention without encouraging unnecessary medication. Regional strategies should account for local regulations, cattle production models, veterinary access, climate conditions, animal movement patterns, and cold-chain capabilities. Partnerships with veterinarians, universities, producer groups, public agencies, and regulators can strengthen trust and accelerate adoption of responsible bovine respiratory disease treatment solutions.

Research Methodology

This executive summary is developed using a secondary research framework grounded in verified public sources, including veterinary regulatory agencies, animal health authorities, peer-reviewed literature, university extension guidance, industry standards, and international organizations such as WOAH, FAO, WHO, FDA, USDA, EMA, and national agriculture departments.

The analysis triangulates clinical practice trends, antimicrobial stewardship policies, livestock production indicators, regional cattle industry structures, veterinary access conditions, disease management guidance, and technology adoption signals. Insights are interpreted through a market intelligence lens to identify drivers, constraints, regional differences, and strategic implications for bovine respiratory disease treatment stakeholders, while avoiding market sizing, market share, and forecasting assumptions.

Conclusion

Bovine respiratory disease treatment is evolving from product-centered therapy toward integrated, evidence-based respiratory health management. The strongest opportunities are emerging where veterinary oversight, diagnostics, vaccination, data analytics, and responsible antimicrobial use are combined into practical protocols that improve outcomes, reduce preventable losses, and support animal welfare.

As regulatory scrutiny and producer expectations rise, stakeholders that demonstrate clinical value, stewardship alignment, supply reliability, traceability, and digital readiness will strengthen competitive positioning. The future of BRD treatment will be defined by earlier detection, targeted intervention, and collaborative herd health systems that support sustainable cattle production and responsible access to effective veterinary care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Bovine Respiratory Disease Treatment Market, by Product Type

• 7.1. Antibiotics
  • 7.1.1. Beta Lactams
  • 7.1.2. Fluoroquinolones
  • 7.1.3. Macrolides
    • 7.1.3.1. Tilmicosin
    • 7.1.3.2. Tulathromycin
    • 7.1.3.3. Tylosin
  • 7.1.4. Tetracyclines
• 7.2. Vaccines
  • 7.2.1. Inactivated
  • 7.2.2. Live Attenuated

8. Bovine Respiratory Disease Treatment Market, by Route Of Administration

• 8.1. Injectable
  • 8.1.1. Intramuscular
  • 8.1.2. Intravenous
  • 8.1.3. Subcutaneous
• 8.2. Intranasal
• 8.3. Oral

9. Bovine Respiratory Disease Treatment Market, by Treatment Type

• 9.1. Therapeutic Treatment
• 9.2. Preventive Treatment
• 9.3. Metaphylactic Treatment

10. Bovine Respiratory Disease Treatment Market, by Animal Type

• 10.1. Adult Cattle
  • 10.1.1. Beef Cattle
  • 10.1.2. Dairy Cows
• 10.2. Calves
  • 10.2.1. Beef Calves
  • 10.2.2. Dairy Calves
• 10.3. Heifers

11. Bovine Respiratory Disease Treatment Market, by Distribution Channel

• 11.1. Feed Mills
  • 11.1.1. Commercial Mills
  • 11.1.2. Onfarm Mills
• 11.2. Online Pharmacies
  • 11.2.1. Animal Health Platforms
  • 11.2.2. General ERetail

12. Bovine Respiratory Disease Treatment Market, by End-User

• 12.1. Veterinary Hospitals & Clinics
• 12.2. Livestock Farms
• 12.3. Feedlots
• 12.4. Animal Husbandry Organizations
• 12.5. Government Veterinary Programs

13. Bovine Respiratory Disease Treatment Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Bovine Respiratory Disease Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Bovine Respiratory Disease Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aratana Therapeutics, Inc.
• 17.2. Ashish Life Science Pvt. Ltd.
• 17.3. Bimeda Inc.
• 17.4. Boehringer Ingelheim International GmbH
• 17.5. Ceva Sante Animale S.A.
• 17.6. Dechra Pharmaceuticals PLC
• 17.7. Elanco Animal Health Incorporated
• 17.8. Hester Biosciences Ltd.
• 17.9. Huvepharma AD
• 17.10. IDEXX Laboratories, Inc.
• 17.11. India Immunologicals Ltd.
• 17.12. Inovio Pharmaceuticals, Inc.
• 17.13. Intas Pharmaceuticals Ltd.
• 17.14. Kyoritsu Seiyaku Corporation
• 17.15. Med-Pharmex Ltd.
• 17.16. Meiji Holdings Co., Ltd.
• 17.17. Merck & Co., Inc.
• 17.18. Neogen Corporation
• 17.19. Novartis Animal Health
• 17.20. Ourofino Saude Animal S.A.
• 17.21. Phibro Animal Health Corporation
• 17.22. Plumbline Life Sciences
• 17.23. Vetoquinol S.A.
• 17.24. Vetsfarma Ltd.
• 17.25. Virbac S.A.
• 17.26. Zoetis Inc.
• 17.27. Zydus Animal Health and Investments Limited